Genomic evolution shapes prostate cancer disease type.
Date
2024-03-13Author
Woodcock, DJ
Sahli, A
Teslo, R
Bhandari, V
Gruber, AJ
Ziubroniewicz, A
Gundem, G
Xu, Y
Butler, A
Anokian, E
Pope, BJ
Jung, C-H
Tarabichi, M
Dentro, SC
Farmery, JHR
CRUK ICGC Prostate Group
Van Loo, P
Warren, AY
Gnanapragasam, V
Hamdy, FC
Bova, GS
Foster, CS
Neal, DE
Lu, Y-J
Kote-Jarai, Z
Fraser, M
Bristow, RG
Boutros, PC
Costello, AJ
Corcoran, NM
Hovens, CM
Massie, CE
Lynch, AG
Brewer, DS
Eeles, RA
Cooper, CS
Wedge, DC
Type
Journal Article
Metadata
Show full item recordAbstract
The development of cancer is an evolutionary process involving the sequential acquisition of genetic alterations that disrupt normal biological processes, enabling tumor cells to rapidly proliferate and eventually invade and metastasize to other tissues. We investigated the genomic evolution of prostate cancer through the application of three separate classification methods, each designed to investigate a different aspect of tumor evolution. Integrating the results revealed the existence of two distinct types of prostate cancer that arise from divergent evolutionary trajectories, designated as the Canonical and Alternative evolutionary disease types. We therefore propose the evotype model for prostate cancer evolution wherein Alternative-evotype tumors diverge from those of the Canonical-evotype through the stochastic accumulation of genetic alterations associated with disruptions to androgen receptor DNA binding. Our model unifies many previous molecular observations, providing a powerful new framework to investigate prostate cancer disease progression.
Collections
Subject
AR binding
cancer evolution
evotype model
evotypes
ordering
prostate cancer
Research team
Oncogenetics
Language
eng
Date accepted
2024-02-08
License start date
2024-02-28
Citation
Cell Genomics, 2024, pp. 100511 -
Publisher
Elsevier BV